ProQR Therapeutics N.V.
NASDAQ:PRQR · NASDAQ Global Market
+$0.21 today
Vol 1.10M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-82.1%
avg -62.9%
ROIC
-49.8%
avg -43.3%
ROA
-36.0%
avg -37.7%
Analysis
ROA is currently the strongest return metric at -36.0% versus its period average of -37.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel Anton de Boer | Founder, CEO & Executive Director | $1.08M | — | 43 | $0.00 | <0.01% |
Gerard Platenburg | Co-Founder, Chief Scientific Officer & Executive Director | $665,266.00 | — | 62 | $824,388.00 | 0.78% |
Cristina Lopez Lopez | Chief Medical Officer | — | — | 50 | — | — |
Dennis Hom | Chief Financial Officer | — | — | 51 | $0.00 | <0.01% |
Sandra van der Kolk | Junior Financial Controller | — | — | — | — | — |
Sarah Cue Kiely | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Sheila Sponselee | Chief People & Operations Officer | — | — | 42 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.31B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$505.60M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$490.18M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$349.53M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$267.47M
Editas Medicine, Inc.
NASDAQ:EDIT
$257.97M
Zura Bio Limited
NASDAQ:ZURA
$241.88M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$213.17M
Immutep Limited
NASDAQ:IMMP
$55.46M
Mereo BioPharma Group plc
NASDAQ:MREO
$51.40M
Who manages PRQR?
ProQR Therapeutics N.V. (PRQR) lists 7 active executives. The top listed executive is Cristina Lopez Lopez, Chief Medical Officer.
Are PRQR insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.